LED Radiofluidics and Premium Imaging Ink MoU For Developing Devices

LED Radiofluidics Corporation, a preclinical biotechnology firm committed to the development of efficient PET radiotracers, and Premium Imaging Inc, a biotechnology company with extensive experience in the clinical transformation and marketing of radiopharmaceuticals, have signed a strategic cooperation agreement.

The two businesses will collaborate on the development and commercialization of photoredox synthesis-based manufacturing equipment and radiopharmaceuticals. The collaboration, which will use LED's proprietary photocatalytic radiofluorination technology and Premium Imaging's expertise in radiopharmaceutical development and marketing, aims to bring new and improved therapy choices for patients globally.

"Nuclear medicine is a rapidly growing market due to numerous unmet patient needs,” said Zibo Li, PhD, LED co-founder, Professor of Radiology, and Director of the Cyclotron Facility at UNC Chapel Hill. “Doctors can face the dilemma of choosing between high-quality PET tracers for accurate diagnosis, which require complex and difficult on-site preparation, and tracers with easier on-site production that offer only acceptable imaging quality. Therefore, it is urgent for us to develop equipment and products with both simple synthesis procedures and high imaging quality. Our photoredox radiolabeling technology provides an innovative solution for these needs.”

Li added, “We are very pleased to collaborate with Premium Imaging combining their expertise in clinical translation and commercialization with our cutting-edge technology. Together, we aim to bring our products to market in the most efficient and scientifically solid way, so that more patients can benefit from new radiopharmaceuticals as soon as possible."